Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Taylor

Nurse Practitioner Rehoboth Beach, DE Nurse Practitioner

NPI 1790118156 CMS profile 10922640

18947 John J Williams Hwy, Suite 201, Rehoboth Beach, DE 19971

Open in the dashboard

General payments

$4,140

122 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Taylor of Rehoboth Beach, DE is reported in the CMS Open Payments database as having received $4,140 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,286 37
2024 General $531 17
2023 General $1,064 24
2022 General $811 27
2021 General $448 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Taylor
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Melissa Taylor were reported at $1,286. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Melissa Taylor Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $448 $135 $40–$426 $132
2022 $811 $152 $48–$470 $149
2023 $1,064 $166 $54–$529 $160
2024 $531 $173 $55–$556 $164
2025 $1,286 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $892 22 payments
  2. E.R. Squibb & Sons, L.L.C. $781 11 payments
  3. Regeneron Healthcare Solutions, Inc. $446 8 payments
  4. Lilly USA, LLC $377 5 payments
  5. AbbVie, Inc. $372 22 payments
  6. Pfizer Inc. $199 11 payments
  7. Sun Pharmaceutical Industries Inc. $199 10 payments
  8. Novartis Pharmaceuticals Corporation $137 7 payments
  9. Incyte Corporation $108 4 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $100 1 payment
  11. Other $530 21 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,741 117 payments
  2. Education $399 5 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $850 20 payments
  2. SOTYKTU $681 10 payments
  3. LIBTAYO $259 3 payments
  4. SIMPONI ARIA $166 7 payments
  5. STELARA $166 7 payments
  6. SIMPONI $166 7 payments
  7. CIBINQO $166 9 payments
  8. DUPIXENT $163 4 payments
  9. LITFULO $148 8 payments
  10. EBGLYSS $125 1 payment
  11. Other $1,983 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,168

Median for Nurse Practitioner: 389

Drug cost

$230,473

Median for Nurse Practitioner: $21,885

Branded share of claims

6.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx (2 Syringes) Secukinumab Brand 14 $99,359
Taltz Autoinjector Ixekizumab Brand 14 $91,690
Clobetasol Propionate Generic 125 $8,799
Metronidazole Generic 72 $4,781
Ketoconazole Generic 218 $4,380
Fluorouracil Generic 65 $3,593
Doxycycline Hyclate Generic 80 $3,389
Tacrolimus Generic 15 $2,089
Clindamycin Phosphate Generic 32 $1,328
Triamcinolone Acetonide Generic 124 $1,087

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$215,299

Of which drugs: $17,382

Medicare patients

1,378

Average age 75

Services billed

6,096

944 women, 434 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 49%
Ischemic heart disease 31%
Diabetes 21%
Depression 19%
Osteoporosis 18%
Atrial fibrillation 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 21 51 $15,353
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 51 $35

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $195
$195 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $109
$109 — —
Odomzo
  • Sun Pharmaceutical Industries Inc. $29
$29 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $29
$29 14 —
HYRIMOZ
  • Sandoz Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record